Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.61% | -8.40% | -20.85% | -7.13% | 7.67% |
| Total Depreciation and Amortization | -5.38% | 1.52% | 10.02% | 195.23% | -136.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.66% | -18.02% | 47.82% | -4.10% | 425.22% |
| Change in Net Operating Assets | 340.18% | -109.03% | 278.47% | -2,116.86% | 92.27% |
| Cash from Operations | -6.33% | -56.51% | 24.32% | -21.97% | 26.37% |
| Capital Expenditure | -32.71% | 61.03% | -705.32% | -141.03% | 93.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3,763.27% | -97.71% | 343.91% | 80.80% | -535.20% |
| Cash from Investing | 4,874.90% | -98.21% | 339.64% | 80.73% | -545.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 998.05% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | 998.05% |
| Foreign Exchange rate Adjustments | -2,242.59% | 126.73% | 44.96% | -249.19% | 185.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 212.17% | -163.10% | 186.73% | -282.90% | 40.11% |